Sana Biotechnology (SANA) Citigroup’s Biopharma Back to School Summit 2026 summary

Platform development and clinical progress

• Advancing two platforms: hypoimmune cell therapy for type 1 diabetes and in vivo genetic payload delivery using fusogens.

• Hypoimmune platform aims for a functional cure with a single injection, targeting euglycemia without lifelong immunosuppression.

• IND-enabling work for the diabetes program is nearly complete, with clinical, preclinical, and manufacturing milestones progressing well.

• Initial clinical data on immune evasion expected within a month of first patient dosing; full efficacy and consistency data anticipated through 2027.

• Manufacturing process is phase I-ready, with ongoing work to scale for registration and commercial supply.

Regulatory and operational updates

• General alignment with global regulators on release requirements; final approval pending regulatory review.

• Clinical trial protocol and sites are finalized, with extensive site training and collaboration with Mayo Clinic to ensure safe and consistent cell delivery.

• IND acceptance will be disclosed as a material event; rapid transition from IND clearance to first patient dosing is expected.

• Dose optimization will be part of phase I, with a focus on maximizing patient access and efficient use of manufacturing capacity.

Market opportunity and strategic outlook

• Type 1 diabetes represents a large, growing global market with significant unmet need; current standard of care still results in reduced life expectancy.

• Pediatric expansion will follow safety confirmation, with potential to move quickly to younger age groups.

• Manufacturing scalability is a key challenge; progress has been made, but treating tens of thousands annually will require further advances.

• The field remains competitive and proprietary, though some manufacturing technologies may eventually be shared.

• Cash runway extends about a year from last quarter's $160 million balance; additional funding will be sought as needed.